Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treat
The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million.
US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh